Tag: Dravet Syndrome
Jazz Pharmaceuticals to acquire Epidiolex developer GW Pharmaceuticals for $7.2bn
Irish biopharma company Jazz Pharmaceuticals has agreed to acquire British pharma company GW Pharmaceuticals in a cash-cum-stock deal worth $7.2 billion. Upon closing of the ... Read More
Zogenix bags Fintepla FDA approval for Dravet syndrome treatment
Fintepla FDA approval : Zogenix has bagged approval from the US Food and Drug Administration (FDA) for Fintepla (fenfluramine) oral solution, CIV for the treatment ... Read More
Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome
US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate - STK-001 from the US Food and Drug Administration (FDA) ... Read More